Zhejiang Yongning Pharma (China)

Safety of TNF-α inhibitors, IL-17 inhibitors, and JAK inhibitors in the treatment of axial spondyloarthritis: a protocol for a multi-method study integrating FAERS data mining, dose–response network meta-analysis, and drug-target Mendelian randomization

Biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs), including tumor necrosis factor-α inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and Janus kinase inhibitors (JAKi), are standard treatments for axial spondyloarthritis (axSpA). However...